JPWO2021216899A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2021216899A5
JPWO2021216899A5 JP2022563172A JP2022563172A JPWO2021216899A5 JP WO2021216899 A5 JPWO2021216899 A5 JP WO2021216899A5 JP 2022563172 A JP2022563172 A JP 2022563172A JP 2022563172 A JP2022563172 A JP 2022563172A JP WO2021216899 A5 JPWO2021216899 A5 JP WO2021216899A5
Authority
JP
Japan
Prior art keywords
seq
polypeptide
less
antibody
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022563172A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023522676A5 (https=
JP7821741B2 (ja
JP2023522676A (ja
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/028679 external-priority patent/WO2021216899A1/en
Publication of JP2023522676A publication Critical patent/JP2023522676A/ja
Publication of JP2023522676A5 publication Critical patent/JP2023522676A5/ja
Publication of JPWO2021216899A5 publication Critical patent/JPWO2021216899A5/ja
Application granted granted Critical
Publication of JP7821741B2 publication Critical patent/JP7821741B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022563172A 2020-04-22 2021-04-22 動物用のｉｌ４／ｉｌ１３受容体分子 Active JP7821741B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063014090P 2020-04-22 2020-04-22
US63/014,090 2020-04-22
US202063014573P 2020-04-23 2020-04-23
US63/014,573 2020-04-23
PCT/US2021/028679 WO2021216899A1 (en) 2020-04-22 2021-04-22 Il4/il13 receptor molecules for veterinary use

Publications (4)

Publication Number Publication Date
JP2023522676A JP2023522676A (ja) 2023-05-31
JP2023522676A5 JP2023522676A5 (https=) 2024-05-02
JPWO2021216899A5 true JPWO2021216899A5 (https=) 2024-05-02
JP7821741B2 JP7821741B2 (ja) 2026-02-27

Family

ID=78270112

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022563172A Active JP7821741B2 (ja) 2020-04-22 2021-04-22 動物用のｉｌ４／ｉｌ１３受容体分子

Country Status (10)

Country Link
US (1) US20240270819A1 (https=)
EP (1) EP4139344A4 (https=)
JP (1) JP7821741B2 (https=)
KR (1) KR20230005880A (https=)
CN (1) CN116034112A (https=)
AU (1) AU2021259785A1 (https=)
BR (1) BR112022021204A2 (https=)
CA (1) CA3173927A1 (https=)
MX (1) MX2022013149A (https=)
WO (1) WO2021216899A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102460040B1 (ko) 2016-04-27 2022-11-01 애브비 인코포레이티드 항-il-13 항체를 이용한 il-13 활성이 유해한 질환의 치료 방법
WO2018156180A1 (en) 2017-02-24 2018-08-30 Kindred Biosciences, Inc. Anti-il31 antibodies for veterinary use
US11970526B2 (en) 2017-04-21 2024-04-30 Elanco Us Inc. IL4/IL13 receptor molecule for veterinary use
BR112020002871A2 (pt) 2017-08-15 2020-07-28 Kindred Biosciences, Inc. variantes fc de igg para uso veterinário
US12428466B2 (en) 2018-10-25 2025-09-30 Elanco Us Inc. IL4/IL13 receptor molecule for veterinary use
WO2025141037A1 (en) * 2023-12-28 2025-07-03 Elanco Animal Health Gmbh Il-4/il-13 and il-4/il-13/il-31 receptor trap constructs

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998023289A1 (en) * 1996-11-27 1998-06-04 The General Hospital Corporation MODULATION OF IgG BINDING TO FcRn
SG10201404273QA (en) 2003-12-23 2014-10-30 Genentech Inc Novel anti-il 13 antibodies and uses thereof
AU2005219837A1 (en) 2004-02-27 2005-09-15 Regeneron Pharmaceuticals, Inc. IL-4/IL-13 sepecific polypetides and therapeutic uses thereof
EP2596802A1 (en) * 2011-11-23 2013-05-29 PLS-Design GmbH Pharmaceutical composition for treatment of allergic reactions
US20170290889A1 (en) * 2016-04-11 2017-10-12 New York University Methods and compositions for treating dysbiosis and gastrointestinal and inflammatory disorders
CN110267674A (zh) * 2016-07-08 2019-09-20 奥美药业有限公司 包含瘦素的融合蛋白及其生产和使用方法
WO2018073185A1 (en) 2016-10-17 2018-04-26 Vetoquinol Sa Modified antibody constant region
US11970526B2 (en) * 2017-04-21 2024-04-30 Elanco Us Inc. IL4/IL13 receptor molecule for veterinary use
WO2024145280A2 (en) * 2022-12-27 2024-07-04 Invetx, Inc. Polypeptides with altered binding to neonatal fc receptor (fcrn) and methods of use
EP4642795A2 (en) * 2022-12-27 2025-11-05 Invetx, Inc. Polypeptides with altered binding to neonatal fc receptor (fcrn) and methods of use

Similar Documents

Publication Publication Date Title
US20250092108A1 (en) ENGINEERED IL-2 Fc FUSION PROTEINS
CN113194984A (zh) 兽用的与新生儿Fc受体(FcRn)结合改变的Fc变体
Silacci et al. Linker length matters, fynomer-Fc fusion with an optimized linker displaying picomolar IL-17A inhibition potency
JP2020517262A5 (https=)
AU2003284895B2 (en) IL-1 receptor based antagonists and methods of making and using
JP7821741B2 (ja) 動物用のｉｌ４／ｉｌ１３受容体分子
JP2012515556A5 (https=)
JP2008511337A5 (https=)
CN102216323B (zh) 用于调节慢性炎症反应和治疗自身免疫性疾病的源自il-4的肽
CN110573626B (zh) 抗体选择方法
AU2018254542B2 (en) IL4/IL13 receptor molecule for veterinary use
KR20120046274A (ko) 항체 생성의 최적화 방법
Patel et al. Sequence of the dog immunoglobulin alpha and epsilon constant region genes
JPWO2021216899A5 (https=)
CN112262213A (zh) 新型抗pad2抗体
RU2009126545A (ru) МУЛЬТИМЕРНЫЕ ПОЛИПЕПТИДЫ Fc-РЕЦЕПТОРА, ВКЛЮЧАЮЩИЕ МОДИФИЦИРОВАННЫЙ Fc-ДОМЕН
Fiedler et al. Use of thiophilic adsorption chromatography for the one-step purification of a bacterially produced antibody Fab fragment without the need for an affinity tag
JP2019172702A (ja) 目的とする含量で不純物を含むＴＮＦＲ−Ｆｃ融合タンパク質の製造方法
CN116375880A (zh) 融合蛋白及其制备方法和应用
RU2830231C2 (ru) Варианты fc-области с измененным связыванием с неонатальным fc-рецептором (fcrn) для применения в ветеринарии
WO2021251438A1 (ja) エリスロポエチンポリペプチドを含む融合タンパク質
JP2006282521A (ja) ニワトリキメラ抗体およびその利用
JPWO2023112028A5 (https=)
CN117866103A (zh) 一种抗破伤风双特异性抗体及其制备方法与应用
HK40017956A (en) Antibody selection method